The role of sacubitril/valsartan in treatment of chronic heart failure
Abstract
Resume: In recent years, widespread use of a combination of sacubitrile / walsartan, a new drug for the treatment of chronic heart failure, has also begun. Thus, with the introduction of the sacubitrile molecule, the pathogenetic treatment of chronic heart failure has been completed. Thus, a number of studies have been conducted in recent years to study the role of natriuretic peptide levels in the pathogenesis of chronic heart failure. And the fact that this newly discovered molecule has a positive effect on the level of sodium peptide in the blood has a positive effect on the progression of heart failure in general.
References
. Ponikowski P., Stefan D., Khalid F. The Global Burden of Heart Failure. ESC : Heart Failure Preventing disease and death worldwide, 2014; 4
Savarese G., Lund L., Global Public Health Burden of Heart Failure. Cardiac Failure Review. 2017; 3: 7-11
Ponikowski P., Stefan D., Khalid F. Heart failure: preventing disease and death worldwide. ESC Heart Failure. 2014; 1: 4-25
Əzizov V. Ə., Ürək çatışmazlığı. Daxili xəstəliklər 2012; 446-447
Ponikowski P., Stefan D., Khalid F. The Global Burden of Heart Failure. ESC : Heart Failure Preventing disease and death worldwide . 2014; 4-9
Ponikowski P., Adriaan A., Stefan D. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). European Heart Journal .2016; 27: 2129–2200
Gheorghiade M,, Shah A.,Vaduganathan M. Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics’, clinicians’, industry's, regulators’, and payers’ perspective. Heart Fail Clin 2013; 9: 285–290
Ambrosy A., Fonarow G., Butler J. The global health and economic burden of hospitalizations for heart failure. J Am Coll Cardiol 2014; 63: 1123–1133
Белеленков Ю. И. Всегда пи необходима тройная комбинация при лечении больных с хронической сердечной недостаточностью? Выбор третьего нейрогормонального блокатора. Терапевтический архив. 2008: 9; 5-12
Yusifli R. Ə. Məmmədova F.D. Xəlilova X. Ə. Xroniki ürək çatışmazlığı olan xəstələrdə ağır ödem sindromlu dekompensasiyanın baş vermə səbəbləri və müalicəsinin əsasları. Sağlamlıq 2016: 6; 61-67
John J.V., MiltonP., Akshay S., et at. for the PARADIGM-HF Investigators and Committees* Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. Int J ardiol. 2018; 264: 118-123. doi: 10.1016/j.ijcard. 2018.03.121.
Pellicori P., J ufen Z., John G.F., Andrew L. What proportion of patients with chronic heart failure are eligible for sacubitril–valsartan? Europian Journal of Heart Failure. 2017; 19(6): 34-37 doi.org/10.1002/ejhf.788
Søren L., Pardeep S., Iain S., Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial and et at for the PARADIGM-HF Investigators and Committees Circulation: Heart Failure. 2016; 9: 49-51
Dany J., Nicolas M., Michel G. et at Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design ESC Heart Failure. 2018; 5(3): 14-16. doi.org/ 10.1002/ ehf2. 12270
Zacà V. Sacubitril/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: a cost-effectiveness analysis. J Cardiovasc Med (Hagerstown). 2018; 19 (10): 597-605. doi:10.2459/JCM. 0000000000000708
Keywords
sacubitril / valsartan хроническая сердечная недостаточность
сакубитрил / валсартан Xroniki ürək çatışmazlığı
sakubitril / valsartan